| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff0a2adb9a476065363e1ff7d552c1b8 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-00772
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-0017
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-00781
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5575 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2012-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_579fba88cb013d3cb28ddf5c4a8acb19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a98b969dfe64786ae8c6805a93aaaa8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e44b895fee3d8315f910f1682472d10c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86cf58dd22398302faa19ac1e79fd967
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9aac9c940a3f38e4b8a2f229266aff97 |
| publicationDate |
2017-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3120834-A1 |
| titleOfInvention |
Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
| abstract |
A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a first punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent. |
| priorityDate |
2011-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |